Tri Locum Partners’s RAPT Therapeutics RAPT Stock Holding History

Tri Locum Partners’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,018	Closed	-$1.77M	–	46
2021 Q4	$1.77M	Buy	+6,018	New	+$1.61M	0.7%	26

Other funds holding RAPT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KXA

KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Tri Locum Partners's RAPT Position: Q1 2022 in Review

Tri Locum Partners sold out of RAPT Therapeutics (RAPT) in Q1 2022, closing a stake of 6,018 shares — an estimated $1.77M sold.

Tri Locum Partners first reported a position in RAPT in Q4 2021 and held it in 1 quarter. The position peaked at $1.77M in Q4 2021. 85 funds tracked by Wall St. Rank hold RAPT as of Q1 2022.

Tri Locum Partners reported no remaining RAPT Therapeutics position as of Q1 2022 after selling out during the quarter.
Tri Locum Partners sold 6,018 RAPT Therapeutics shares in Q1 2022, an estimated $1.77M.
Tri Locum Partners first reported a position in RAPT Therapeutics in Q4 2021 and held it in 1 quarter.
Tri Locum Partners's RAPT Therapeutics position peaked at $1.77M in Q4 2021.
85 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2022.

Based on Tri Locum Partners's 13F filing for Q1 2022, filed 16 May 2022.